Please provide your email address to receive an email when new articles are posted on . Nicox announced that the first patient has been screened in its Whistler phase 3b clinical trial of NCX 470, a ...
Showing similar results as the first phase III trial completed in 2022, Nicox SA’s nitric oxide-donating bimatoprost eye drop, NCX-470, met the primary endpoint in the phase III Denali trial for ...
You may notice vision loss and changing glaucoma symptoms if your prescribed medicated eye drops stop working. Your doctor can help test your visual field and determine if you need different drops or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results